Koji Ando

10PUBLICATIONS
28CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsRadiation therapyPredictive and prognostic markersObstetrics and gynaecology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Apr 16, 2026
Proteasome inhibitor, ixazomib prevents topoisomerase-I degradation and reverses irinotecan resistance in colorectal cancer.

|Jan 27, 2026
IAP Antagonists Selectively Eliminate Therapy-Induced Senescent Cancer Cells via TNFα-Independent Apoptosis.

Hiroaki Ochiiwa, Takeshi Wakasa, Yuki Kataoka

|Jan 05, 2026
Integrating Immune Checkpoint Inhibitors With Total Neoadjuvant Therapy in Proficient Mismatch Repair Rectal Cancer.

Yoshinori Kagawa, Jun Watanabe, Koji Ando

|Feb 01, 2025
A phase two trial evaluating FOLFIRI plus aflibercept after failure of FOLFOXIRI plus bevacizumab in patients with unresectable metastatic colorectal cancer.

Koji Ando, Hironaga Satake, Mototsugu Shimokawa

|Nov 18, 2024
DNA-dependent protein kinase inhibitor as a sensitizer of radiotherapy in locally advanced rectal cancer.

Yoshinori Kagawa, Jun Watanabe, Koji Ando

|Nov 06, 2024
Phase II study of long-course chemoradiotherapy followed by consolidation chemotherapy as total neoadjuvant therapy in locally advanced rectal cancer in Japan: ENSEMBLE-2.

Yoshinori Kagawa, Koji Ando, Mamoru Uemura

Pageof 2

Frequent Collaborators

6 joint publications

Eiji Oki

4 joint publications

Jun Watanabe

4 joint publications

Yoshinori Kagawa

2 joint publications

Daisuke Kotani